Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr.
Portfolio Pulse from
Chris DeMuth Jr. highlights Arbutus Biopharma as a promising investment due to its potential litigation value from IP claims against Pfizer and Moderna related to COVID-19 vaccine technology.
January 30, 2025 | 9:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arbutus Biopharma is highlighted as a promising investment due to its potential litigation value from IP claims against Pfizer and Moderna related to COVID-19 vaccine technology.
The potential litigation value from IP claims against major companies like Pfizer and Moderna could lead to significant financial gains for Arbutus Biopharma, making it a promising investment.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80